scholarly journals Different protein composition of low-calorie diet differently impacts adipokine profile irrespective of weight loss in overweight and obese women

2018 ◽  
Vol 28 (2) ◽  
pp. 133-142 ◽  
Author(s):  
R. Mateo-Gallego ◽  
I. Lamiquiz-Moneo ◽  
S. Perez-Calahorra ◽  
V. Marco-Benedí ◽  
A.M. Bea ◽  
...  
2008 ◽  
Vol 18 (7) ◽  
pp. 477-482 ◽  
Author(s):  
T. Tzotzas ◽  
T.D. Filippatos ◽  
A. Triantos ◽  
E. Bruckert ◽  
A.D. Tselepis ◽  
...  

2011 ◽  
Vol 2011 ◽  
pp. 1-8 ◽  
Author(s):  
Joel Kullberg ◽  
Magnus Sundbom ◽  
Arvo Haenni ◽  
Susanne Freden ◽  
Lars Johansson ◽  
...  

Background. Recently, we found large reductions in visceral and subcutaneous fat one month after gastric bypass (GBP), without any change in liver fat content.Purpose. Firstly to characterize weight loss-induced lipid mobilization after one month with preoperative low-calorie diet (LCD) and a subsequent month following GBP, and secondly, to discuss the observations with reference to our previous published findings after GBP intervention alone.Methods. 15 morbidly obese women were studied prior to LCD, at GBP, and one month after GBP. Effects on metabolism were measured by magnetic resonance techniques and blood tests.Results. Body weight was similarly reduced after both months (mean: −8.0 kg,n=13). Relative body fat changes were smaller after LCD than after GBP (−7.1±3.6% versus−10±3.2%,P=.029,n=13). Liver fat fell during the LCD month (−41%,P=.001,n=13) but was unaltered one month after GBP (+12%).Conclusion. Gastric bypass seems to cause a greater lipid mobilization than a comparable LCD-induced weight loss. One may speculate that GBP-altered gastrointestinal signalling sensitizes adipose tissue to lipolysis, promoting the changes observed.


2021 ◽  
Author(s):  
Sahar Cheshmeh ◽  
Maysa Ghayyem ◽  
Firoozeh Khamooshi ◽  
Neda Heydarzadeh ◽  
Niloofar Hojati ◽  
...  

Abstract PurposePolycystic ovary syndrome (PCOS) is a common cause of endocrine disorder and infertility among womenin which is related with low grade inflammation. Therefore, this current randomized, double-blind, placebo-controlledclinical trial assessed the effects of green cardamom supplementation on inflammatory markers and gene expressionamong obese women with PCOS.MethodsWe included 194 obese PCOS women that gave all of them low calorie diet. These subjects were randomlydivided in two studied groups including intervention with 3 g/day green cardamom (n=99) and placebo groups (n=95).Anthropometric indices, androgen hormones, and inflammatory factors (tumor necrosis factor-a (TNF-α), Interleukin6 (IL-6), and C- reactive protein (CRP)) were assessed before and after four months intervention. Their TNF-α, IL-6,and CRP genes expression level were measured using reverse transcription-polymerase chain reaction (RT-PCR)method.ResultsAnthropometric indices were improved in both two studied groups (P<0.001). Among androgen hormonesluteinizing hormone, androstenedione, and dehydroepiandrosterone were significantly decreased (P<0.001), as wellas, follicle-stimulating hormone was significantly increased (P<0.001) in the green cardamom group. Our findingsshowed that TNF-α, IL-6, and CRP serum were significantly decreased after the intervention with green cardamomplus low calorie diet (P<0.001). In addition, the expression level of TNF-α and CRP genes were significantly decreasedin intervention groups (P<0.001).ConclusionsThis present study support the beneficial anti-inflammatory effect of green cardamom on theinflammatory status in the PCOS women.Level of evidenceLevel I, randomized clinical trialTrial registrationThis trial was registered with the Iranian Clinical Trials Registry (registration number:IRCT20200608047697N1). 1 August, 2020; https://www.irct.ir/trial/48748


1991 ◽  
Vol 37 (Supplement) ◽  
pp. S57-S64 ◽  
Author(s):  
Tetsuo SHOJI ◽  
Yoshiki NISHIZAWA ◽  
Hidenori KOYAMA ◽  
Satoshi HAGIWARA ◽  
Hideyuki ARATANI ◽  
...  

2018 ◽  
Vol 29 (1) ◽  
pp. 54-60 ◽  
Author(s):  
Kamthorn Yolsuriyanwong ◽  
Komdej Thanavachirasin ◽  
Kimberly Sasso ◽  
Lauren Zuro ◽  
Jessica Bartfield ◽  
...  

BMJ Open ◽  
2019 ◽  
Vol 9 (11) ◽  
pp. e031431
Author(s):  
Simon Birk Kjær Jensen ◽  
Julie Rehné Lundgren ◽  
Charlotte Janus ◽  
Christian Rimer Juhl ◽  
Lisa Møller Olsen ◽  
...  

IntroductionThe success rate of weight loss maintenance is limited. Therefore, the purpose of this study is to investigate the maintenance of weight loss and immunometabolic health outcomes after diet-induced weight loss followed by 1-year treatment with a glucagon-like peptide-1 receptor agonist (liraglutide), physical exercise or the combination of both treatments as compared with placebo in individuals with obesity.Methods and analysisThis is an investigator-initiated, randomised, placebo-controlled, parallel group trial. We will enrol expectedly 200 women and men (age 18–65 years) with obesity (body mass index 32–43 kg/m2) to adhere to a very low-calorie diet (800 kcal/day) for 8 weeks in order to lose at least 5% of body weight. Subsequently, participants will be randomised in a 1:1:1:1 ratio to one of four study groups for 52 weeks: (1) placebo, (2) exercise 150 min/week+placebo, (3) liraglutide 3.0 mg/day and (4) exercise 150 min/week+liraglutide 3.0 mg/day. The primary endpoint is change in body weight from randomisation to end-of-treatment.Ethics and disseminationThe trial has been approved by the ethical committee of the Capital Region of Denmark and the Danish Medicines Agency. The trial will be conducted in agreement with the Declaration of Helsinki and monitored to follow the guidelines for good clinical practice. Results will be submitted for publication in international peer-reviewed scientific journals.Trial registration number2015-005585-32


Sign in / Sign up

Export Citation Format

Share Document